Business Wire

Visa Installments Expands to Australia, Offering a New Way to Buy Now, Pay Later

7.10.2021 13:00:00 CEST | Business Wire | Press Release

Share

Visa (NYSE: V), the world’s leader in digital payments, today announced the expansion of Visa Installments in Australia in partnership with ANZ, one of the country’s largest financial institutions, and merchant payment provider Quest. The Visa solution lets Australian shoppers access popular “Buy Now, Pay Later” (BNPL) financing via their existing ANZ credit cards, during checkout and without any extra steps.

Visa’s fintech programs have been helping to enable the growth of installments globally since as early as 2017. With the Visa Installments Solution, Visa is now bringing the flexibility of BNPL financing that Australians love to the cards already in eligible consumers’ wallets and phones - for use during in-store and online checkout.

The Visa Installments Solution provides the underlying technology for issuers and acquirers in the Visa network to offer BNPL functionality to their customers. This means financial institutions can add BNPL as a feature for credit cardholders, on their already approved credit lines, in whatever terms are right for their customers. And likewise, acquirers on the network can activate the ability to accept installments for any of their retailers that accept Visa. First launched as a pilot in 2019, the solution has expanded to the U.S., Canada, Malaysia, Russia—and now, Australia.

When qualified shoppers use their ANZ Visa credit cards at the in-store terminal or while shopping online at participating merchants, they’ll be able to select a repayment term displayed on the screen during the purchase process. Quest, a leading provider of merchant payment technology, is working with Visa to enable businesses to accept Visa Installments quickly and seamlessly - merchants with Quest-integrated point-of-sale (POS) software will not need to make any software changes to enable the solution.

With the Visa Installments Solution, participating lenders can offer a more flexible range of repayment plans – from three months to 24 months, with no interest in some cases– and customers can view their installment purchases, balances and repayment information directly in their existing banking apps.

This solution will be welcomed by Australian consumers, with a recent Visa survey finding that 90% of participants showed a high likelihood of using an installments option from their issuing bank, and 85% saying installments would improve their relationship with their card provider1.

“There is overwhelming demand in Australia for BNPL financing through consumers’ existing, trusted financial institution,” said Julian Potter, Visa’s Group Country Manager for Australia, New Zealand, and South Pacific. “We’re proud to work with our long-standing partner, ANZ, on the first roll-out of Visa Installments that has been built from the ground up – at the network level – to be deployed in-store and across ecommerce channels without the need for consumers or businesses to do anything new. Now Australians’ credit cards can buy now, pay later, too.”

“We are always on the lookout for products and services that add genuine value to our customers and the ability to make installment payments is a key feature that many of them want,” ANZ Head of Cards and Personal Lending Mike Shurlin said. “Visa Installments ticks all the boxes in terms of its flexibility, security and ease-of-use, allowing us to add more optionality and create better experiences for our credit card customers.”

“We have worked with Visa on a number of customer solutions in the past, including a wide range of mobile payments and loyalty solutions, and we share the same focus: making payments simple, flexible and secure for our customers. We look forward to working with Visa to bring this exciting new payment option to our customers,” Mr Shurlin added.

“Quest is delighted to be working closely with Visa to offer installment payments through our family of trusted payment terminals, already used by many of Australia’s best known retail brands. In making this available through our omnichannel payment gateway solutions, retailers will be able to offer installment payment options to their customers both online and in-store,” said Luke Fuller, Head of SME and Alternative Payments at Quest.

About Visa Inc.

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa, https://usa.visa.com/visa-everywhere/blog.html and @VisaNews.

About ANZ

ANZ is among the top four banks in Australia, the largest banking group in New Zealand and Pacific, and among the top 100 banks in the world by market capitalisation. ANZ's history dates back to 1835 with the Group operating in 32 markets globally with representation in Australia, New Zealand, Asia, Pacific, the Middle East, Europe, and America. ANZ provides a range of banking and financial products and services to more than eight million Retail, Commercial and Institutional customers, and employs more than 39,000 people worldwide. ANZ's strategy is focused on improving the financial wellbeing of our customers; having the right people who listen, learn and adapt; putting the best tools and insights into their hands; and, focusing on those few things that really add value to customers and doing them right the first time.

About Quest Payment Systems

With headquarters in Melbourne, Quest is an Australian owned technology company providing a diverse and innovative range of omnichannel payment solutions to businesses and financial institutions, both locally and abroad. As the country’s leading full-service payment solution supplier, delivering Australia’s only locally designed and manufactured range of payment terminal hardware, Quest delivers both mass market and custom solutions drawing on over twenty years of development expertise. Quest’s portfolio of solutions include countertop, unattended and mobile payment terminal hardware, software, gift card and online payment solutions, EMV smartcard, contactless, communications and transaction routing solutions as well as bespoke hardware and software design, professional consulting and manufacturing services.

1 Research on installments solutions was commissioned by Visa and conducted among Australian credit card holders online in September 2020 by UX Army.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Caylah Novak
cnovak@visa.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye